The Outlook on Getting Regulatory-Approved Bevacizumab to Market

PODCAST EPISODE 262

Click here to watch the video version of this podcast.


OIS Podcast host Firas Rahhal, MD, of ExSight Ventures and Retina Vitreous Associates sits down with not one but two members of Outlook Therapeutics’ C-Suite staff, Terry Dagnon and Jeff Evanson. We learn about what kind of collaborations and strategies are necessary behind the scenes at Outlook and learn more about the company’s road to bringing ONS-5010/Lytenava (bevacizumab-vikg) – potentially the only Food and Drug Administration-approved form of bevacizumab for the eye – to market. From studies, dosing, pricing, and other considerations, they cover it all. Press play now and listen in on this innovative conversation!

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our Hosts

Ehsan Sadri
ehsan sadri
Firas Rahhal
FirasRahhal
Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.